<DOC>
	<DOCNO>NCT01876368</DOCNO>
	<brief_summary>This study ass efficacy safety LCZ696 comparison olmesartan essential hypertensive patient adequately responsive olmesartan</brief_summary>
	<brief_title>Efficacy Safety LCZ696 Compared Olmesartan Essential Hypertensive Patients Not Responsive Olmesartan</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<criteria>patient mild moderate hypertension , untreated currently take antihypertensive therapy treat patient ( use antihypertensive drug within 4 week prior first visit ) must office msSBP ≥ 145 mmHg &lt; 180 mmHg washout epoch 4 week runin epoch untreated patient ( either newly diagnose patient history hypertension take antihypertensive drug least 4 week prior first visit ) must offcie msSBP ≥ 150 mmHg &lt; 180 mmHg screen 1 week screening must office msSBP ≥ 145 mmHg &lt; 180 mmHg 4 week runin epoch patient must successfully complete ABPM pas technical requirement qualify randomization Malignant severe hypertension ( grade 3 WHO classification ; msDBP ≥110 mmHg and/or msSBP ≥ 180 mmHg ) History angioedema , drugrelated otherwise History evidence secondary form hypertension , include limited following : renal parenchymal hypertension , renovascular hypertension ( unilateral bilateral renal artery stenosis ) , coarctation aorta , primary hyperaldosteronism , Cushing 's disease , pheochromocytoma , polycystic kidney disease ( PKD ) , druginduced hypertension Patients previously enter LCZ696 study randomize enrolled receive active drug treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>hypertension ,</keyword>
	<keyword>LCZ696 ,</keyword>
	<keyword>olmesartan</keyword>
</DOC>